11th Jun 2014 06:51
LONDON (Alliance News) - Pharmaceuticals company AstraZeneca PLC Wednesday said that 43 abstracts reporting results of the company's research and development in diabetes have been accepted for presentation at the 74th Scientific Sessions of the American Diabetes Association in San Francisco next week.
In a statement, the company said it will present clinical data from studies evaluating several approved products, including Forxiga, Bydureon, Onglyza, as well as investigational combination of saxagliptin and dapagliflozin.
The sessions take place between June 13 and June 17.
By Steve McGrath; [email protected]; @SteveMcGrath1
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca